MedPath

Verastem

Verastem logo
🇺🇸United States
Ownership
Public
Established
2010-01-01
Employees
73
Market Cap
-
Website
http://www.verastem.com
Introduction

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Clinical Trials
Related News

A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-09-26
Last Posted Date
2017-01-30
Lead Sponsor
Verastem, Inc.
Target Recruit Count
5
Registration Number
NCT02913716

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Phase 1
Terminated
Conditions
Pancreatic Cancer
Interventions
Drug: Part A- VS-4718, nab-paclitaxel, gemcitabine
Drug: Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine
Drug: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine
First Posted Date
2016-01-11
Last Posted Date
2017-07-27
Lead Sponsor
Verastem, Inc.
Target Recruit Count
13
Registration Number
NCT02651727
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Phase 1
Terminated
Conditions
Relapsed Malignant Mesothelioma
Interventions
First Posted Date
2015-02-26
Last Posted Date
2017-01-30
Lead Sponsor
Verastem, Inc.
Target Recruit Count
21
Registration Number
NCT02372227
Locations
🇺🇸

The University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Memorial Sloane Kettering Cancer Center, New York, New York, United States

🇬🇧

University of Leicester, Leicester, United Kingdom

and more 1 locations

Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

Phase 1
Withdrawn
Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2014-08-13
Last Posted Date
2017-01-27
Lead Sponsor
Verastem, Inc.
Registration Number
NCT02215629

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Phase 2
Terminated
Conditions
Malignant Pleural Mesothelioma
Interventions
First Posted Date
2013-12-06
Last Posted Date
2024-02-20
Lead Sponsor
Verastem, Inc.
Target Recruit Count
35
Registration Number
NCT02004028
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Phase 1
Terminated
Conditions
Non Hematologic Cancers
Metastatic Cancer
Lymphoma
Interventions
First Posted Date
2013-11-25
Last Posted Date
2017-01-27
Lead Sponsor
Verastem, Inc.
Target Recruit Count
75
Registration Number
NCT01991938
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer
Lung Cancer
Interventions
First Posted Date
2013-09-27
Last Posted Date
2017-04-13
Lead Sponsor
Verastem, Inc.
Target Recruit Count
55
Registration Number
NCT01951690
Locations
🇺🇸

University of Colorado Cancer Center, Anschutz Medical Campus, Denver, Colorado, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 6 locations

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Phase 1
Completed
Conditions
Non Hematologic Cancers
Interventions
First Posted Date
2013-09-16
Last Posted Date
2017-03-09
Lead Sponsor
Verastem, Inc.
Target Recruit Count
9
Registration Number
NCT01943292
Locations
🇯🇵

Kinki University Hospital, Osaka, Japan

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Phase 2
Terminated
Conditions
Malignant Pleural Mesothelioma
Interventions
Drug: Placebo
First Posted Date
2013-06-06
Last Posted Date
2017-01-30
Lead Sponsor
Verastem, Inc.
Target Recruit Count
344
Registration Number
NCT01870609
Locations
🇺🇸

University of California San Francisco Medical Center, San Francisco, California, United States

🇺🇸

Cleveland Clinic Florida, Weston, Florida, United States

🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

and more 70 locations

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

Phase 1
Terminated
Conditions
Non Hematologic Cancers
Metastatic Cancer
Interventions
First Posted Date
2013-05-08
Last Posted Date
2017-07-28
Lead Sponsor
Verastem, Inc.
Target Recruit Count
48
Registration Number
NCT01849744
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy